Tresiba and Psoriasis - a phase IV clinical study of FDA data
We study 18,736 people who have side effects when taking Tresiba. Psoriasis is found, especially among people who are female, 60+ old, have been taking the drug for < 1 month, also take Otezla and have Psoriatic arthropathy.
The phase IV clinical study analyzes which people take Tresiba and have Psoriasis. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
18,736 people reported to have side effects when taking Tresiba.
Among them, 57 people (0.3%) have Psoriasis.
What is Tresiba?
Tresiba has active ingredients of insulin degludec. It is used in type 1 diabetes. Currently, eHealthMe is studying from 18,888 Tresiba users.
What is Psoriasis?
Psoriasis (immune-mediated disease that affects the skin) is found to be associated with 2,531 drugs and 1,640 conditions by eHealthMe. Currently, we are studying 477,421 people who have Psoriasis.
Number of Tresiba and Psoriasis reports submitted per year:
Time on Tresiba when people have Psoriasis *:
- < 1 month: 50 %
- 1 - 6 months: 50 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 0.0 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
Gender of people who have Psoriasis when taking Tresiba *:
- female: 76.36 %
- male: 23.64 %
Age of people who have Psoriasis when taking Tresiba *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 3.12 %
- 40-49: 6.25 %
- 50-59: 21.88 %
- 60+: 68.75 %
Common drugs people take besides Tresiba *:
- Otezla: 23 people, 40.35%
- Metformin: 19 people, 33.33%
- Novolog: 11 people, 19.30%
- Trulicity: 8 people, 14.04%
- Cymbalta: 8 people, 14.04%
- Fiasp: 7 people, 12.28%
- Escitalopram: 7 people, 12.28%
- Ozempic: 6 people, 10.53%
- Cosentyx: 6 people, 10.53%
- Salagen: 6 people, 10.53%
Common side effects people have besides Psoriasis *:
- Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 9 people, 15.79%
- High Blood Pressure: 7 people, 12.28%
- Joint Pain: 7 people, 12.28%
- Malaise (a feeling of general discomfort or uneasiness): 6 people, 10.53%
- Fatigue (feeling of tiredness): 6 people, 10.53%
- Rashes (redness): 6 people, 10.53%
- Dry Eyes (lack of adequate tears): 5 people, 8.77%
- Diarrhea: 5 people, 8.77%
- Headache (pain in head): 5 people, 8.77%
- Dry Mouth: 5 people, 8.77%
Common conditions people have *:
- Diabetes: 8 people, 14.04%
- Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 8 people, 14.04%
- High Blood Pressure: 4 people, 7.02%
- Type 2 Diabetes: 3 people, 5.26%
- Depression: 3 people, 5.26%
- Pain: 2 people, 3.51%
- Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 3.51%
- Cough: 2 people, 3.51%
- Moyamoya Disease (a disease in which certain arteries in the brain are constricted. blood flow is blocked by the constriction): 2 people, 3.51%
- Seizures (abnormal excessive or synchronous neuronal activity in the brain): 2 people, 3.51%
* Approximation only. Some reports may have incomplete information.
Do you take Tresiba and have Psoriasis?Check whether Psoriasis is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Mohagheghi MA, Omranipur R, Ensani F, Ghannadan A, Shahriaran S, Samiee F, Sedighi Z, "A Case of Advanced Unicentric Retroperitoneal Castleman's Disease, Associated With Psoriasis", Acta Medica Iranica, 2017 May .
- Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
- Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .
Tresiba side effects by duration, gender and age:
- Tresiba side effects (18,888 reports)
Psoriasis treatments and more:
- Psoriasis (477,421 reports)
Common drugs associated with Psoriasis:
- Cosentyx: 26,984 reports
- Enbrel: 26,259 reports
- Humira: 23,088 reports
- Otezla: 21,096 reports
- Methotrexate: 10,887 reports
- Stelara: 6,001 reports
- Prednisone: 4,329 reports
- Remicade: 3,490 reports
- Metformin: 2,821 reports
- Aspirin: 2,803 reports
All the drugs that are associated with Psoriasis:
- Psoriasis (2,531 drugs)
Common conditions associated with Psoriasis:
- Rheumatoid arthritis: 6,377 reports
- High blood pressure: 3,552 reports
- Crohn's disease: 3,134 reports
- Pain: 1,905 reports
All the conditions that are associated with Psoriasis:
- Psoriasis (1,640 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on insulin degludec (the active ingredients of Tresiba) and Tresiba (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Meloxicam and Pamelor drug interaction - 6 seconds ago
- Myrbetriq and Central Nervous System Lesion - 10 seconds ago
- Zide and Heart Palpitations - 10 seconds ago
- Sertraline and Citanest drug interaction - 13 seconds ago
- Fluconazole and Hepatic Congestion - 19 seconds ago
- Avandamet and Hypotension - 27 seconds ago
- Enhertu and Dyspepsia Aggravated - 29 seconds ago
- Ddavp and Blood Sodium Increased - 30 seconds ago
- Physiosol In Plastic Container and Breathing Difficulty - 30 seconds ago
- Ibrance and Iron Deficiency Anaemia - 50 seconds ago